Bruce Barclay, president and chief executive officer, Phil Ankeny, senior vice president and chief financial officer, and Ken Melrose, chairman of the board, will discuss financial results and achievements for the fiscal year ended September 30, 2008 as well as results from the first quarter of fiscal year 2009, and speak about the Company's strategy and prospects.
To access the webcast, go to the investor relations portion of the Company's website at www.surmodics.com, on the day of the Annual Meeting and click on the webcast icon. In addition, the Annual Meeting audio and slide presentation will be archived on the Company's website following the meeting.
About SurModics, Inc.
SurModics, Inc. is a leading provider of drug delivery and surface modification technologies to the healthcare industry. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in improved patient outcomes. Core offerings include: drug delivery technologies (coatings, microparticles, nanoparticles, and implants); surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. SurModics is headquartered in Eden Prairie, Minnesota and its Brookwood Pharmaceuticals subsidiary is located in Birmingham, Alabama. For more information about the Company, visit www.surmodics.com. The content of SurModics' website is not part of this release or part of any filings the Company makes with the SEC.
SOURCE: SurModics, Inc.
Phil Ankeny, Senior Vice President and Chief Financial Officer